SLOW PROGRESSION OF MEMORY

Experimental drug works best for Alzheimer's patients treated as early as possible

Experimental drug works best for Alzheimer's patients treated as early as possible. The drug, donanemab, has been shown to slow progression of memory and thinking problems by about a third, but that rate doubles to 60% if the drug is started when patients are only mildly impaired, according to new trial data presented at the Alzheimer's Association International Conference in Amsterdam.